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Abstract
Background: Serotonin (5-HT) is a neurotransmitter with important roles in the regulation of neurobehavioral processes,
particularly those regulating affect in humans. Drugs that potentiate serotonergic neurotransmission by selectively
inhibiting the reuptake of serotonin (SSRIs) are widely used for the treatment of psychiatric disorders. Although the
regulation of serotonin synthesis may be an factor in SSRI efficacy, the effect of chronic SSRI administration on 5-HT
synthesis is not well understood. Here, we describe effects of chronic administration of the SSRI citalopram (CIT) on 5-HT
synthesis and content in the mouse forebrain.
Methodology/Principal Findings: Citalopram was administered continuously to adult male C57BL/6J mice via osmotic
minipump for 2 days, 14 days or 28 days. Plasma citalopram levels were found to be within the clinical range. 5-HT synthesis
was assessed using the decarboxylase inhibition method. Citalopram administration caused a suppression of 5-HT synthesis
at all time points. CIT treatment also caused a reduction in forebrain 5-HIAA content. Following chronic CIT treatment,
forebrain 5-HT stores were more sensitive to the depleting effects of acute decarboxylase inhibition.
Conclusions/Significance: Taken together, these results demonstrate that chronic citalopram administration causes a
sustained suppression of serotonin synthesis in the mouse forebrain. Furthermore, our results indicate that chronic 5-HT
reuptake inhibition renders 5-HT brain stores more sensitive to alterations in serotonin synthesis. These results suggest that
the regulation of 5-HT synthesis warrants consideration in efforts to develop novel antidepressant strategies.
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Introduction
Depression is a devastating illness and one of the major causes of
disability in the world, affecting over 120 million people [1,2].
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed
as a first-line treatment for depression and many other psychiatric
disorders [3–5]. The primary pharmacological activity of SSRIs is
inhibition of the serotonin transporter (SERT) (P31645.1, Uni-
ProtKB/Swiss-Prot), which is responsible for the reuptake of serotonin
(5-HT) from the extracellular space back into the nerve terminals
that release it [6,7]. Inhibition of this transport alters the
spatiotemporal dynamics of serotonin signaling such that activity in
theserotonergicneuroncausesgreaterandmoreprolongedincreases
in extracellular serotonin than would normally occur [8–12].
SSRIs are generally administered continuously for months or
years, often indefinitely; however, the precise effects of chronic
reuptake inhibition on serotonin and serotonergic neurotransmission
are not completely understood [13–20]. Although the primary
pharmacological targets of SSRIs have been well characterized for
decades, several issues regarding their use remain unresolved.
Clinical evidence suggests that while SSRIs are generally effective
for the treatment of manypsychiatricdisorders, a substantialnumber
of patients will not respond to the SSRI initially prescribed or even
to any SSRI, and other patients will attain only a partial remission of
symptoms[5,21,22].AnotherpossiblelimitationofSSRItreatmentis
a latencyof severalweeks fortherapeuticeffectsto occur[6,14,23,24]
(but see [25]). The mechanisms downstream of SERT blockade that
are responsible for the therapeutic effects of SSRIs remain unknown,
despite recent advances [6]. Given the high affinity of SSRIs for
SERT [26], it is generally believed that these downstream events are
initiated and sustained by effects on serotonergic neurotransmission
[27]. Altogether,efforts to develop novel antidepressant strategiesare
hampered by a lack of fundamental understanding of how SSRIs
affect multiple aspects of brain function.
SSRIs affect, secondarily to reuptake inhibition, many aspects of
serotonergic neurotransmission, including autoreceptor function
and serotonergic neuron activity [14,28]. Some of these effects
have been proposed to influence therapeutic response [14,29]. In
particular, 5-HT synthesis warrants consideration as a factor in
SSRI efficacy. In the brain, serotonin is synthesized from the
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hydroxylase enzyme (TPH2; accession Q8IWU9, UniProtKB/
Swiss-Prot), which is expressed, in the brain, exclusively in
serotonergic neurons. In vitro, the rate of neurotransmitter
synthesis is an important factor in monoaminergic physiology
[30]. In vivo, 5-HT synthesis rate is regulated by many factors,
such as stress [31–33] and the availability of tryptophan [34–36].
Pharmacological inhibition of 5-HT synthesis can induce a rapid
relapse of depression symptoms in SSRI-treated patients with
remitted depression, an effect which is not readily observed in
subjects with no history of SSRI administration [27,37–44] (also
see [45]). Tryptophan itself is considered to be ineffective as an
antidepressant [46]; however, tryptophan co-administered with a
5-HT reuptake inhibitor may be more effective as an antidepres-
sant than the reuptake inhibitor administered alone [47–50].
These findings raise the question of how chronic SSRI
administrationitselfmightaffect5-HTsynthesis.Thereissubstantial
evidence that acute administration of SSRIs suppresses serotonin
synthesis throughout the brain [51–57]. SSRI administration can
rapidly trigger physiological responses, such as suppression of
serotonergic neuronal activity, which gradually dissipate upon
chronic treatment [14,28,58]. These adaptations may be required
for the beneficial effects of antidepressants to emerge [14,24]. In
patients, SSRIs are generally administered continuously for months
or years. It is not clear how chronic, continuous administraton of
SSRIs affects 5-HT synthesis rate. Prior studies addressing this issue
have reported contradictory results, perhaps due to methodological
issues [55,59–62]. For several of these studies [59–61], the SSRI was
administered by repeated injection, which can lead to large daily
fluctuations in plasma drug levels [63]. In addition, 5-HT synthesis
was assessed some time after the final SSRI injection, to allow the
drug to ‘wash out’ of circulation. Drug washout may induce
physiological changes which are opposite to the effect of the drug
continuously administered [64,65]. For the other studies addressing
this issue, 5-HT synthesis was estimated using an assay whose
validity is not universally accepted [55,62,66–68]. (For a review of
these studies, see Discussion.)
Although SSRI treatment produces robust increases in extracel-
lular 5-HT, there is evidence that SSRI administration can actually
deplete brain stores of 5-HT and of its major metabolite, 5-
hydroxyindoleacetic acid (5-HIAA) [64,69–77], as would be
predicted if 5-HT synthesis were suppressed and serotonergic
neurons were unable to effectively recapture released 5-HT.
In this study, we explored how chronic reuptake blockade
affects forebrain 5-HT synthesis rate and forebrain 5-HT and 5-
HIAA content over the course of chronic treatment in mice. We
chose to administer citalopram; although many SSRIs such as
fluoxetine and paroxetine have significant pharmacological
interactions with targets other than SERT [78–80], citalopram
(CIT) is extremely selective for SERT [26]. To address limitations
of previous studies, we used osmotic minipumps, which deliver
drug at a constant rate, to generate steady-state blood concentra-
tions of citalopram; we omitted drug washout; and we quantified
plasma citalopram levels in order to determine whether they
approximated clinically relevant concentrations. In order to
address whether CIT administration renders 5-HT stores more
sensitive to the suppression of 5-HT synthesis, we also examined
forebrain 5-HT and 5-HIAA content in CIT- and vehicle-treated
mice following acute inhibition of amino acid decarboxylase.
Results
Male adult C57BL6/J mice were treated using osmotic
minipumps to deliver a 10% citalopram or saline vehicle solution
at a constant low rate (0.25 mL/hour) for 2, 14 or 28 days. The
dose and route of administration were chosen to approximate
typical pharmacokinetics in patients, in whom CIT rapidly reaches
a steady-state plasma concentration with relatively little variation
throughout the day [81–83]. We used high performance liquid
chromatography coupled with mass spectroscopy (HPLC-MS) to
quantify CIT concentrations in plasma collected at the time of
sacrifice. Plasma levels in CIT-treated mice ranged from 176 to
661 nM, with a mean of 383 nM (Fig. 1A). These levels are
comparable to steady-state CIT concentrations found in the blood
of patients receiving a typical dose of citalopram. Fredricson
Overo et al [84] and Pederson et al [85] observed a mean CIT
concentration of approximately 245 nM in patients receiving
40 mg per day, whereas Dufour et al observed blood levels
between 157 and 616 nM with 40–60 mg/day dosage [86]. In
CIT-treated mice, plasma levels were not significantly affected by
Figure 1. Chronic citalopram treatment: Plasma drug concen-
trations and inhibitory effect on 5-HT synthesis. A. Plasma levels
of CIT were assessed by HPLC-MS in C57BL6/J adult male mice following
2 days, 2 weeks or 4 weeks of citalopram (CIT) (10% solution) or saline
(SAL) administration by osmotic minipump (0.25 mL/hour). As no
significant amount of citalopram was found in mice implanted with
vehicle-filled minipumps for 2, 14 or 28 days, these groups were
combined. Numbers of mice: 2-day CIT, n=5; 2-week CIT, n=10; 4-week
CIT, n=4; SAL, n=19. B. 5-HTP accumulation, an index of 5-HT
synthesis, in the forebrains of mice following chronic administration of
CIT or vehicle by osmotic minipump. NSD-1015 (100 mg/kg IP) was
injected 30 minutes before sacrifice. 5-HTP accumulation was signifi-
cantly suppressed at all time points (*p,0.001, **p,0.01, ***p,0.05,
Bonferroni post-ANOVA test). Numbers of mice: 2-day CIT-treated, n=6;
2-day SAL-treated, n=6; 2-week CIT-treated, n=8; 2-week SAL-treated,
n=7; 4-week CIT-treated, n=7; 4-week SAL-treated, n=10.
doi:10.1371/journal.pone.0006797.g001
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duration, p=0.48).
5-HT synthesis rate was assessed using the decarboxylase
inhibition method. 3-hydroxybenzylhydrazine dihydrochloride
(NSD-1015) was injected intraperitoneally (IP) 30 minutes prior
to sacrifice (100 mg/kg). Under normal circumstances, the amino
acid decarboxylase enzyme (AADC, accession P20711, Uni-
ProtKB/Swiss-Prot) catalyzes the decarboxylation into 5-HT of
5-hydroxytryptophan (5-HTP), the product of tryptophan hydrox-
ylation. NSD-1015 inhibits AADC, leading to the accumulation of
5-hydroxytryptophan (5-HTP), which is normally present only in
minute concentrations due to its rapid decarboxylation. 5-HTP
can be precisely identified and quantified by HPLC coupled to
electrochemical detection (HPLC-ED) [35,56,87–90]. Since tryp-
tophan hydroxylation is the rate-limiting reaction in 5-HT
synthesis, the amount of 5-HTP that accumulates over a specific
period of time is considered an index of the rate of 5-HT synthesis
[35,51,53,56,87–91]. The dose of NSD-1015 that we chose is the
lowest dose which produces near-maximal inhibition of amino
acid decarboxylation in mice [87]. We did not observe any
fatalities with this dose of NSD-1015.
For each time point, CIT- and vehicle-treated mice and samples
were handled in parallel by an experimenter blinded to treatment
group. To determine whether the duration of minipump
implantation had an effect on forebrain 5-HTP accumulation in
vehicle-treated mice, we performed a one-way ANOVA analysis of
the effect of treatment duration on 5-HTP accumulation in SAL-
treated mice. In order to evaluate differences between pairs of
groups while adjusting for multiple comparisons, we also
performed Bonferroni post tests. We observed a significant effect
of treatment duration on 5-HTP accumulation in vehicle-treated
mice (p=0.0004, ANOVA) (Fig. 1B). Post tests confirmed that
there was significant difference in 5-HTP accumulation between
2-day and 2-week SAL-treated groups (p,0.01) and between 2-
day and 4-week SAL-treated groups (p,0.001) but not between 2-
week and 4-week SAL-treated groups (p.0.05). We performed
identical ANOVA analyses to test for the effect of treatment
duration on other neurochemical parameters in SAL-treatment
mice. Treatment duration had a significant effect on forebrain 5-
HT and 5-HIAA in mice treated with NSD-1015 (p=0.009 and
p=0.005, respectively) and not treated with NSD-1015 (p=0.002
and p=0.0005) (Figs. 2 and 3).
Citalopram treatment resulted in a sustained suppression of 5-
HT synthesis rate in the forebrain (Fig. 1B). We performed a two-
way ANOVA analysis to test for the effects of drug administration
and treatment duration on 5-HT synthesis in mice treated with
SAL or CIT for 2, 14 or 28 days. We also performed a Bonferroni
post test to evaluate the effect of treatment at each individual time
point. CIT treatment had a significant overall effect on 5-HT
synthesis (p,0.0001, ANOVA). Treatment duration also had a
significant effect and there was an interaction between treatment
and treatment duration (p=0.0015 and p=0.026, respectively,
ANOVA). 5-HTP accumulation was significantly lower in CIT-
treated mice than in control mice at all time points. The effect of
CIT appeared to be greatest following 2 days of treatment (36%
decrease in mean 5-HTP accumulation, p,0.001, Bonferroni post
test) and was comparable at 2 weeks (24% decrease, p,0.01) and 4
weeks (20% decrease, p,0.05). These results indicate that 5-HT
synthesis remains significantly inhibited following a prolonged
treatment with a highly selective SSRI at a clinically relevant dose.
To determine whether SSRI-induced reduction in 5-HT
synthesis would lead to decreased brain 5-HT content, we
examined 5-HT content in the forebrains of mice treated for 2,
14 and 28 days with CIT or vehicle (Fig. 2A). For this experiment,
no NSD-1015 was administered prior to sacrifice. Data were
analyzed as for 5-HTP (above). A significant overall effect of
treatment on 5-HT was observed (p=0.04, ANOVA); however,
Bonferroni post tests did not demonstrate a significant effect of
CIT treatment at any single time point (p.0.05, all time points).
These data therefore do not allow us to draw an unequivocal
conclusion; however, they suggest that CIT treatment with a
clinically relevant dose may have the potential to cause a modest
reduction in forebrain 5-HT content.
Multiple mechanisms may exist to buffer brain 5-HT content
and stabilize neurotransmission in the face of reduced 5-HT
synthesis. One potential mechanism for buffering brain 5-HT
content is reduced intracellular degradation of 5-HT into 5-HIAA.
To test whether SSRI administration affects 5-HT degradation,
we quantified brain 5-HIAA content using HPLC-ED (Fig. 3A &
B). Brain 5-HIAA content was reduced in CIT-treated mice, both
with and without NSD-1015 administration (p,0.0001, ANOVA)
(Fig. 3). In the absence of NSD-1015 treatment, the magnitude of
the CIT effect was comparable after 2 days (36% decrease,
p,0.001, Bonferroni post test) and 2 weeks of treatment (39%
decrease, p,0.01) and was not significant at 28 days of treatment
(p.0.05). The ratio of 5-HT to 5-HIAA has been considered to be
an index of 5-HT turnover. We observed a significant effect of
CIT administration on this ratio (p,0.0001, ANOVA), with a
Figure 2. Effect of chronic citalopram treatment on forebrain 5-
HT content. A. 5-HT forebrain content in mice treated chronically with
CIT or vehicle. 5-HT content was not significantly affected by CIT
treatment at any single time point (p.0.05, Bonferroni post-ANOVA
test). However, CIT treatment caused a significant overall reduction in 5-
HT as determined by ANOVA (p,0.05). Numbers of mice: 2-day CIT-
treated, n=8; 2-day SAL-treated, n=8; 2-week CIT-treated, n=8; 2-week
SAL-treated, n=9; 4-week CIT-treated, n=7; 4-week SAL-treated, n=7.
B. 5-HT forebrain content in mice treated chronically with CIT or vehicle
and acutely with NSD-1015 (100 mg/kg IP) 30 minutes before sacrifice.
Forebrain 5-HT content was reduced in mice treated with CIT for 2
weeks (*p,0.01, Bonferroni post test) and 4 weeks (*p,0.01) but not 2
days (p.0.05). Numbers of mice: 2-day CIT-treated, n=6; 2-day SAL-
treated, n=6; 2-week CIT-treated, n=8; 2-week SAL-treated, n=7; 4-
week CIT-treated, n=7; 4-week SAL-treated, n=10.
doi:10.1371/journal.pone.0006797.g002
Citalopram and 5-HT Synthesis
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6797significant reduction following 2 days (p,0.001, Bonferroni post
test) and 2 weeks (p=0.01) but not 4 weeks (p.0.05) of treatment
(Fig. S1).
To test the hypothesis that 5-HT reuptake inhibition renders
brain 5-HT stores more sensitive to the suppression of 5-HT
synthesis, we examined forebrain 5-HT content in CIT- and
vehicle-treated mice following acute injection of NSD-1015
(100 mg/kg IP 30 minutes before sacrifice). This NSD-1015
treatment is thought to cause a near-complete inhibition of
monoamine synthesis in mice [87]. In this condition, chronic CIT
administration caused a significant reduction in brain 5-HT
content (p,0.0001, ANOVA) (Fig. 2B). This effect was compa-
rable after 2 weeks (18% decrease; p,0.01, Bonferroni post test)
and after 4 weeks of treatment (20% decrease; p,0.01) and was
not significant after 2 days (p.0.05).
Discussion
In this study, we demonstrate that chronic treatment with
citalopram, a widely prescribed and highly selective SERT
inhibitor [3,26], causes a suppression of 5-HT synthesis in the
mouse brain. This effect is most pronounced following 2 days of
CIT administration and persists with prolonged treatment. This
effect was observed using a clinically relevant dosing regimen;
osmotic minipumps were used to deliver CIT at a constant rate,
producing stable plasma concentrations in the clinical range [81–
84]. This effect was observed using a dissection of the entire right
hemi-forebrain, suggesting that this effect is occurring in many,
perhaps all, regions of the forebrain. Nevertheless, we cannot infer,
based on our results, what effect CIT may have on 5-HT synthesis
in specific forebrain nuclei or in brain regions not analyzed, such
as the raphe nuclei.
Numerous investigators have reported that acute treatment with
SSRIs produces a suppression of 5-HT synthesis [51,53,54,56,57].
Although several previous studies have addressed the issue of how
chronic SSRI administration affects 5-HT synthesis, methodolog-
ical considerations limit the interpretation of these results. Moret
et al [59] and Stenfors et al [60] reported increased 5-HT synthesis
rate with chronic treatment with citalopram and fluoxetine,
respectively, whereas Esteban et al [61] reported no effect of
chronic fluoxetine. For these studies, SSRIs were administered by
repeated injection and administration was withheld following the
chronic treatment and prior to determination of 5-HT synthesis
rate in order to allow the SSRI to ‘wash out’. It is notable,
however, that SSRI washout can induce rapid changes in
serotonergic physiology which are opposite to the effect of the
same drug administered continuously [65,92]. Notably, Trouvin et
al reported reduced brain 5-HT and 5-HIAA content following
chronic fluoxetine administration; this effect reversed rapidly with
washout [64]. As patients typically take SSRIs for months or years
without interruption, the clinically relevant physiological effects of
SSRIs occur while the drug is at steady-state levels. Therefore, we
did not include a washout period in our study design.
In previous studies of chronic SSRIs and 5-HT synthesis, SSRIs
were administered by repeated injection [59–61]. This treatment
regimen can lead to large daily fluctuations in plasma citalopram
in rodents [63] which complicate the interpretation of resulting
effects. Yamane et al used osmotic minipumps to administer
chronic paroxetine without washout and reported reduced brain
trapping of the radiotracer a-[
14C]-methyl-tryptophan, which is
consistent with reduced 5-HT synthesis [55]. However, these
authors reported no effect of chronic citalopram in wild-type rats
[62]. There is disagreement as to whether or not a-[
14C]-methyl-
tryptophan trapping is a reliable measure of 5-HT synthesis [66–
68]. The decarboxylase inhibition assay used in the present study
has the advantage that 5-HTP can be unambiguously identified
and quantified by HPLC-ED; however, as a caveat, 5-HT
synthesis is assessed while monoamine systems are significantly
disrupted by inhibition of synthesis of multiple active neurotrans-
mitters [93].
In vehicle-treated mice, we also observed a significant effect of
time on 5-HT synthesis such that 5-HT synthesis was elevated
following 2 days of treatment as compared to following 14 or 28
days. Although the design of our study does not allow us to
interpret the specific causes for this effect, we may speculate that
peri-operative stress could have affected serotonergic function in
the 2-day treatment group. Stress influences serotonergic function,
particularly 5-HT synthesis [31,33]; moreover, interactions
between neurochemical responses to stress and to SSRI admin-
istration have also been reported [94]. Thus, stress and CIT
administration may interact to influence our results regarding 5-
HT synthesis and other neurochemical measures. As all mice were
of the same age at the time of minipump implantation, aging over
the course of the experiment could also have affected our results.
How might our data regarding 5-HT synthesis inhibition be
explained in terms of monoamine neurophysiology? As SSRI
administration causes a rapid increase in extracellular 5-HT [95],
Figure 3. Reduced forebrain 5-HIAA in mice treated with CIT. A.
5-HIAA forebrain content in mice treated chronically with CIT or vehicle.
5-HIAA content was significantly lower in mice treated with CIT for 2
days (*p,0.001, Bonferroni post-ANOVA test) or 2 weeks (**p,0.01)
but not 4 weeks (p.0.05). Numbers of mice: 2-day CIT-treated, n=8; 2-
day SAL-treated, n=8; 2-week CIT-treated, n=8; 2-week SAL-treated,
n=9; 4-week CIT-treated, n=7; 4-week SAL-treated, n=7. B. 5-HIAA
forebrain content in mice treated chronically with CIT or vehicle and
acutely with NSD-1015 (100 mg/kg IP) 30 minutes before sacrifice. 5-
HIAA content was lower in CIT-treated mice at all time points
(*p,0.001, Bonferroni post-ANOVA test). Numbers of mice: 2-day CIT-
treated, n=6; 2-day SAL-treated, n=6; 2-week CIT-treated, n=8; 2-week
SAL-treated, n=7; 4-week CIT-treated, n=7; 4-week SAL-treated, n=10.
doi:10.1371/journal.pone.0006797.g003
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exerts a negative feedback control of 5-HT synthesis in
serotonergic neurons [96]. The mechanism whereby this might
occur remains unknown. Serotonergic autoreceptors could provide
a simple and plausible mechanism; in fact, 5-HT autoreceptor
activation can suppress 5-HT synthesis in vivo [54,61,97].
However, activation of the known 5-HT autoreceptors does not
appear to be required for acute suppression of 5-HT synthesis by
citalopram [54]. Furthermore, the functional activation of
autoreceptors is thought to dissipate over the course of SSRI
treatment [14,29] whereas the effect on synthesis persists.
Citalopram might also affect 5-HT synthesis by reducing brain
availability of tryptophan; however, this is unlikely as many
antidepressants have been reported to increase brain tryptophan
by inhibiting metabolism of tryptophan in the liver [98–101].
Studies of tryptophan hydroxylase enzyme function in CIT-treated
mice could elucidate the as-yet unknown mechanisms underlying
the effect we observed.
Our results provide an interesting contrast to previous genetic
studies of the relationship between 5-HT synthesis and SERT
function [102,103]. Unlike SSRI treatment, reported null
mutations in SLC24A4, the gene encoding SERT, result in a
complete inactivation of SERT function from embryogenesis
through adulthood [102,104,105]. Also unlike SSRI treatment,
these manipulations have initial effects which are completely
SERT-specific. In mice, an engineered null mutation in mice
causes an increase in 5-HTP accumulation in vivo [103]. In
SLC24A4 null mutant rats generated by forward mutagenesis
[102], in vivo 5-HTP accumulation has not been reported. In brain
tissue from both mice and rats, no increase was observed in the in
vitro maximal enzymatic activity of tryptophan hydroxylase
[102,103], suggesting that the effect of the mouse mutation on
5-HT synthesis is related to a feature of in vivo serotonergic
circuitry [103]. The difference in the effects of genetic inactivation
and pharmacological blockade of SERT may be related to the
magnitude and timing of the physiological effects of these
manipulations. Although both manipulations cause a large
increase in extracellular 5-HT, null mutations also cause a
dramatic depletion of tissue 5-HT [102,103] and may disrupt
serotonergic neuron development, as suggested by the reported
decrease in serotonin cell number in null mutant mice [105] (but
not rats [106]). The mouse null mutation has behavioral effects
which are very different from those SSRI administration [105], as
does neonatal treatment with SSRIs [78,107,108], which also may
impair the development of serotonergic neurons [78,108]. Null
mutations in SLC24A4 may therefore cause a profound disruption
in serotonin physiology and may, as a result, trigger homeostatic
adaptations in serotonin synthesis which are not engaged with
SSRI treatment.
What might be the functional consequences of chronic
suppression of 5-HT synthesis? Neurotransmitter synthesis and
its regulation are fundamental features of neurophysiology;
however, the functional significance of regulation of 5-HT
synthesis [31,109,110] is not well understood. Prolonged suppres-
sion of 5-HT synthesis by SSRI treatment might deplete 5-HT
brain stores, which could limit or otherwise affect SSRI response.
We did not observe a clear effect of CIT treatment on forebrain 5-
HT content. Trouvin et al reported 20–50% decreases in total 5-
HT tissue content in several brain regions following a 21-day
treatment with fluoxetine [64,74]. Dygalo et al [71] and Caccia et
al [69,111] reported comparable results, although this effect was
not observed in all brain regions examined. Marsteller also
observed reduced tissue 5-HT following chronic treatment with
CIT [73]. This effect was, however, not observed in two studies of
chronic fluoxetine administration [72,75]. Taken together, these
reports suggest that SSRI treatment may produce a modest
reduction in brain 5-HT content, with unknown functional
consequences.
Multiple mechanisms may exist to buffer neurotransmitter
stores and stabilize neurotransmission in the face of reduced
synthesis. For example, glutamatergic synaptic transmission is
remarkably resistant to manipulation of glutamate synthesis [112].
Under conditions of reuptake blockade, intracellular 5-HT might
be buffered by a suppression of 5-HT degradation. In accord with
this hypothesis, we observed a reduction of brain 5-HIAA content
with CIT treatment, as has been observed previously
[64,69,71,72,74–76,111] (but see [73,76,77]). 5-HT degradation
may be suppressed due to a direct SSRI-induced inhibition of
monoamine oxidases, as has been reported [75,76] (but see [113]).
Reduced 5-HT reuptake could also shift the cellular compart-
mentalization of 5-HT, increasing the extracellular concentration
at the expense of intracellular stores by effectively trapping 5-HT
outside cells. This could in principle lead to a reduction in 5-HIAA
production, as the monoamine oxidases, which reside in the
mitochondrial membrane, can only metabolize intracellular 5-HT.
However, available data suggest that less than 1% of total 5-HT is
extracellular under normal conditions [114,115]. Given that
extracellular 5-HT increases only several fold with SSRI
administration, this mechanism is unlikely to be sufficient to
account for the reduction in 5-HIAA we observed.
Although CIT-induced reductions of forebrain 5-HT synthesis
were not accompanied by substantial reductions in forebrain 5-HT
stores, we hypothesized that chronic reuptake blockade might
render 5-HT stores more vulnerable to decarboxylase inhibition.
This hypothesis is supported by the fact that serotonergic neurons
have two sources of 5-HT: synthesis from tryptophan and reuptake
from the extracellular space. When reuptake is inhibited, brain 5-
HT content should be more dependent on 5-HT synthesis and
might be depleted more rapidly in response to synthesis inhibition.
Accordingly, when we challenged mice by administering NSD-
1015 acutely prior to sacrifice, brain 5-HT was reduced in mice
treated chronically with CIT. In accord with this finding, SERT
null mutant animals have much more pronounced depletion of
brain 5-HT content than wild-type animals in response to
tryptophan depletion [36] and in response to inhibition of AADC
[103]; SERT inactivation also leads to exaggerated neurochemical
and behavioral responses to drugs that enhance 5-HT synthesis
[116,117]; and tryptophan depletion has marked effects on
extracellular 5-HT in SSRI-treated rats but not in control rats
[92,118]. It is not clear why this depletion effect would be observed
with 14 or 28 days but not 2 days of treatment. It is possible that
after a relatively brief CIT treatment, serotonergic neurons might
have a greater reservoir of intracellular 5-HT, or a heightened
tendency to retain intracellular 5-HT due to the reduction in
neuronal activity which dissipates with extended treatment.
These results suggest that SSRI administration might cause a
form of ‘‘serotonergic vulnerability’’ [119] whereby serotonergic
neurotransmission becomes more sensitive to environmental or
genetic factors that would inhibit 5-HT synthesis, such as an
unbalanced diet [120,121]. In fact, tryptophan depletion has
pronounced depressive effects on patients taking SSRIs [27,37–
44]. Conversely, genetic deficits in 5-HT synthesis could limit
SSRI efficacy. For example, a putative genetic deficiency in 5-HT
synthesis in mice [122–124] may be associated with blunted
responses to citalopram [56,125]. Genetic influences on trypto-
phan hydroxylase function have been proposed to affect SSRI
response in humans, although present evidence is not conclusive
[126–131].
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augmentation of 5-HT synthesis might be beneficial for the
treatment of depression if administered in conjunction with a 5-
HT reuptake inhibitor. In patients, tryptophan augmentation of 5-
HT reuptake therapy is supported by a limited number of clinical
trials [47,48]. These data are, however, not definitive [46,50] and
large follow-up clinical trials have not been reported. In an animal
model, behavioral and physiological relevance of the suppression
of 5-HT synthesis by SSRIs could be assessed by augmenting 5-
HT synthesis in SSRI-treated animals using tryptophan loading
[92]. Altogether, our results suggest that the regulation of 5-HT




All procedures involving mice were approved by the UCSF
Institutional Animal Care and Use Committee. 6-week-old male
C57BL/6J mice were obtained from Jackson Laboratories and
housed under standard conditions (7 AM to 7 PM light; PicoLab
5053 diet ad libitum; individually aerated cages; Specific Pathogen
Free facility; 3 mice per cage). 2–3 weeks following shipment, mice
underwent surgery between 1 and 4 PM. Mice were anesthetized
with 2–4% isoflurane and osmotic minipumps (Alzet) were
implanted as per manufacturer’s instructions. Minipumps (Model
1002 for 2-day and 2-week treatment groups; Model 2004 for 4-
week treatment groups) were filled with sterile 0.9% NaCl vehicle
(Hospira) or 10% citalopram hydrobromide (provided by
Lundbeck A/S) dissolved in vehicle. Citalopram solution was
briefly warmed to 37uC to facilitate dissolution and was sterile
filtered. Citalopram-filled pumps produced a dose of approxi-
mately 24 mg/kg/day.
Groups & Treatments
Mice were divided into 12 groups. 6 groups of mice were
implanted with CIT-filled minipumps and 6 with SAL-filled
minipumps. For 6 groups of mice (CIT- and SAL-treated mice
sacrificed following 2, 14 or 28 days of treatment), dissections were
performed without additional treatment (other than minipump
implantation) prior to sacrifice. For the remaining 6 groups of mice
(CIT- and SAL-treated mice sacrificed following 2, 14 or 28 days
of treatment), all mice received 2 injections prior to sacrifice: saline
1 hour prior and NSD-1015 (3-hydroxybenzylhydrazine dihydro-
chloride, Sigma, 54880) (100 mg/kg IP) 30 minutes prior. All
treatments, dissections and analyses were performed in parallel for
groups corresponding to the same time point (e.g., mice treated for
2 weeks with CIT and injected with NSD-1015 prior to sacrifice
were dissected and analyzed in parallel with mice treated with
SAL for 2 weeks and injected with NSD-1015 prior to sacrifice).
Numbers of mice for NSD-1015-treated groups were as follows: 2-
day CIT-treated, n=6; 2-day SAL-treated, n=6; 2-week CIT-
treated, n=8; 2-week SAL-treated, n=7; 4-week CIT-treated,
n=7; 4-week SAL-treated, n=10.. Numbers of mice for non-
NSD-1015-treated groups were as follows: 2-day CIT-treated,
n=8; 2-day SAL-treated, n=8; 2-week CIT-treated, n=8; 2-
week SAL-treated, n=9; 4-week CIT-treated, n=7; 4-week SAL-
treated, n=7.
Sample collection and preparation
All sample preparation and analysis was performed by an
experimenter blinded to treatment group. Following the appro-
priate treatment period, mice were sacrificed by decapitation
under brief isoflurane anesthesia between 1 and 4 PM. Trunk
blood was collected in K2EDTA tubes (365974, BD) and spun at
1000 g for 10 minutes. Plasma supernatant was stored at 280uC.
Brains were rapidly dissected by removing the pineal gland,
olfactory bulb and cerebellum and sectioning coronally immedi-
ately caudal to the hypothalamus. Forebrains were hemisected
saggitally. Brain samples were frozen immediately over powdered
dry ice and stored at 280uC. Right forebrain samples were then
homogenized using a glass mortar and pestle in 600 mL cold 0.1 M
perchloric acid (Sigma) and spun at 16000 g for 15 minutes at 4uC.
Supernatant was stored at 280uC and analyzed without further
dilution.
Analysis of plasma citalopram
Plasma citalopram was analyzed by HPLC-MS. Separation was
performed on a reverse phase 15064.6 mm Zorbax Eclipse XDB-
C8 column (Agilent Technologies) with a Zorbax Eclipse XDB C8
guard column (Agilent). The mobile phase consisted of 50% water
and 50% acetonitrile supplemented with 0.1% formic acid and its
flow rate was 0.5 mL/min. A post-column make-up flow of
acetonitrile with 0.1 % formic acid was added to assist spray
formation. For analysis, each 10 ml plasma sample was thoroughly
mixed with 90 ml acetonitrile. After 5 min, samples were spun and
30 mL of the supernatant was injected using an autosampler
(Shimadzu SIL-10, Kyoto, Japan). Citalopram was detected using
an API4000 mass spectrometer consisting of a turbospray interface
(Applied Biosystems). Acquisition was performed in positive
ionization mode with ion spray voltage set at 5.5 kV and probe
temperature of 400uC. The instrument was operated in multi-
reaction-monitoring (MRM) mode for detection of citalopram
(precursor 325, product ion 262) and a standard, Lu-10-202
(precursor 341, product ion 278). Quantification was performed by
the external standard method using the Analyst 1.4.2 data system
(Applied Biosystems). Citalopram peak heights were normalized to
peak heights of Lu-10-202 internal standard.
Analysis of brain 5-HT, 5-HIAA and 5-HTP
5-HT, 5-HIAA and 5-HTP were analyzed by HPLC-ED as
follows: Mobile phase consisted of 50 mM sodium acetate, 0.51
mM EDTA, 0.9 mM 1-octanesulfonic acid sodium salt, and 14%
methanol (pH 4.4) and was delivered at a flow rate of 1 mL/min
using a Shimadzu Prominence pump. Analytes were separated
using a reversed phase SupelcoSil LC-18-DB 58993
15cm64.6mm63um column (Supelco) heated to 30uC. 50 mL
samples were cooled to 12uC in a refrigerated tray and injected
using a Gilson 231 autosampler. The external standard method
was used for quantification. Dihydroxybenzylamine hydrobromide
(Sigma, 858781) was added to each sample and used as an internal
standard. Fresh standards (Sigma) were prepared in acetic acid
and run at beginning of run. Samples were interspersed with
quality control brain sample replicates to monitor sensitivity,
chromatography and sample degradation. Analytes were detected
using a two-electrode electrochemical cell (model 5011, ESA) the
first electrode was set at 50 mV for preoxidation. The second
electrode was set 250 mV for quantification. A Coulochem II
detector (ESA) was used to control the cell. Peak height was
measured using EZChrom Elite software (Scientific Software).
Protein assays
A BCA microplate assay (Pierce 23225) was used for the
determination of protein content in perchloric acid homogenates.
Homogenates were allowed to equilibrate at room temperature.
12 mL of each sample was added to 200 mL BCA working reagent,
prepared as per the manufacturer’s instructions, in quadruplicate
in a flat-bottomed 96-well plate (Nunc). BSA standards were
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adhesive plate covers (ABI) and well vortexed immediately, then
incubated at 37uC for 40 min. Plate covers were removed and
absorbance at 562 nm was read on a SpectroMax 190 plate reader
(Molecular Devices).
Statistical analysis
For all peaks, peak height was normalized to the height of the
internal standard peak and converted to molarity using the
appropriate standard. For single factor comparisons of two groups,
two-tailed Student’s t-test with Welch’s correction was applied. For
multiple-factor comparison, multi-factor ANOVA with Bonferroni
post-test was applied.
Supporting Information
Figure S1 Reduced forebrain 5-HIAA / 5-HT ratio in mice
treated with CIT. 5-HIAA / 5-HT ratio in the forebrains of mice
treated chronically with CIT or vehicle. 5-HIAA / 5-HT ratio
content was significantly lower in mice treated with CIT for 2 days
(*p,0.001, Bonferroni post-ANOVA test) or 2 weeks (**p,0.01)
but not 4 weeks (p.0.05). Numbers of mice : 2-day CIT-treated,
n=8; 2-day SAL-treated, n=8; 2-week CIT-treated, n=8; 2-
week SAL-treated, n=9; 4-week CIT-treated, n=7; 4-week SAL-
treated, n=7.
Found at: doi:10.1371/journal.pone.0006797.s001 (0.30 MB EPS)
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